Glioblastoma Diagnosis Leads to Unconventional Treatment Trial

A 55-year-old man's life was turned upside down when he began experiencing persistent fatigue and unusual changes in his gait. Despite being physically active, Edward Waldner found himself exhausted all the time, which prompted him to seek medical attention.

Waldner's symptoms worsened over time, prompting an emergency department visit where doctors discovered a mass on his brain. The diagnosis was confirmed by an oncologist who revealed that the mass was glioblastoma, a highly aggressive and difficult-to-treat form of brain cancer.

Glioblastoma is notoriously resistant to treatment, with standard care typically involving surgery, radiation, and chemotherapy. Surgeons attempt to remove as much of the tumor as possible, but glioblastoma cells often infiltrate surrounding brain tissue, making complete removal nearly impossible.

Researchers at the University of Calgary are exploring an unconventional approach to battling this deadly cancer: high doses of vitamin B3, also known as niacin.

Waldner was approached by researchers at the University of Calgary to participate in a clinical trial investigating an innovative treatment for glioblastoma. When asked about his decision to join the study, he revealed a willingness to try anything that might help him and others affected by this deadly cancer.

The research is being led by two experts with diverse backgrounds: Gloria Roldan Urgoiti, a medical doctor specializing in brain cancers, and Wee Yong, a neuroscientist who studies how the immune system interacts with the brain. Their collaboration is focused on addressing a critical issue with glioblastoma - its ability to suppress the immune response.

The tumor's interference with the immune system is a major obstacle in fighting glioblastoma, as it weakens the body's natural defenses against cancer cells. The researchers aim to determine whether niacin can restore some of these impaired immune cells and enable them to target and destroy tumor cells.

The idea of using niacin originated from experiments conducted by Yong in his laboratory using mice. These studies showed that niacin treatment led to extended survival rates, prompting the team to move forward with a combined Phase I and II clinical trial in humans.

The clinical trial is designed to evaluate the safety and efficacy of combining controlled release niacin with standard chemotherapy and radiotherapy for patients with glioblastoma multiforme.

According to Yong, a professor at the Cumming School of Medicine, the immune system typically works to prevent tumor growth but this type of brain cancer suppresses it. The researcher believes that niacin treatment can revitalize immune cells so they can effectively target and destroy cancer cells.

The trial aims to determine the highest safe dose of controlled release niacin that can be used in conjunction with standard treatments. Researchers are also looking for evidence that adding niacin may improve a patient's progression-free survival rate, which is measured by how long patients remain alive without their cancer worsening.

To establish whether the trial should continue, researchers have set a threshold: they will stop if the six-month progression-free survival rate fails to show an improvement of at least 20 percent compared with earlier studies.

The trial's early results have been more encouraging than expected, with a significant improvement in cancer progression-free survival rates among participants. In fact, an impressive 82 percent of patients had not experienced any progression of their cancer at six months, marking a notable increase of 28 percent compared to previous studies.

While the findings are promising for this particularly aggressive and incurable form of brain cancer, researchers caution that the results are still preliminary and based on a relatively small group of patients. Further investigation is needed to confirm these early indications of effectiveness.

According to Roldan Urgoiti, clinical associate professor at the CSM, glioblastoma remains one of the most challenging cancers for adults, with little change in patient survival rates over the past 20 years. Any potential breakthrough should be rigorously tested and monitored to ensure safety and efficacy.

The researchers stress that high doses of niacin, while potentially beneficial, require careful medical oversight due to their toxicity at large amounts. The controlled and closely monitored approach used in this clinical trial is crucial to preventing adverse effects associated with excessive vitamin intake.

The clinical trial is expected to enroll a total of 48 participants, with researchers aiming to complete their final analysis by the end of 2026 or early 2027.

Waldner's experience in the study has provided him with an additional treatment option, and his doctors continue to closely monitor his cancer progression. He reports feeling well and expresses gratitude whenever his routine scans show that his condition is stable. This stability is a welcome development for Waldner and his medical team.

The research has received funding from the Canadian Institutes of Health Research and the Alberta Cancer Foundation, supporting the ongoing investigation into the potential benefits of this common vitamin in fighting brain cancer.